FCGR3A and cancer: Even though the correlation between FcγRIIIa polymorphisms and outcome in trastuzumab-treated cancer patients was not confirmed in a recent clinical study [47], the important role of FcγRIIIa in Fc-mediated immune function is not in dispute.